CN116745304A - Ip4-4,6取代的衍生化合物 - Google Patents

Ip4-4,6取代的衍生化合物 Download PDF

Info

Publication number
CN116745304A
CN116745304A CN202280012575.8A CN202280012575A CN116745304A CN 116745304 A CN116745304 A CN 116745304A CN 202280012575 A CN202280012575 A CN 202280012575A CN 116745304 A CN116745304 A CN 116745304A
Authority
CN
China
Prior art keywords
compound
salt
inositol
aspects
myo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280012575.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·D·M·佩雷斯·费勒
M·D·费勒·瑞尼斯
M·F·巴西西
C·萨尔塞多·罗卡
C·塞拉·科马斯
J·L·卡泰纳·鲁伊斯
A·雷巴里亚·索尔德维拉
J·奥尔特加·卡斯特罗
J·佩雷罗·贝斯塔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weifu International Co ltd
Original Assignee
Sanifeld Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifeld Treatment Co ltd filed Critical Sanifeld Treatment Co ltd
Publication of CN116745304A publication Critical patent/CN116745304A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280012575.8A 2021-01-29 2022-01-31 Ip4-4,6取代的衍生化合物 Pending CN116745304A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382075.6A EP4036097A1 (en) 2021-01-29 2021-01-29 Ip4-4,6 substituted derivative compounds
EP21382075.6 2021-01-29
PCT/EP2022/052164 WO2022162206A1 (en) 2021-01-29 2022-01-31 Ip4-4,6 substituted derivative compounds

Publications (1)

Publication Number Publication Date
CN116745304A true CN116745304A (zh) 2023-09-12

Family

ID=74732816

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280012575.8A Pending CN116745304A (zh) 2021-01-29 2022-01-31 Ip4-4,6取代的衍生化合物

Country Status (13)

Country Link
US (1) US20240109924A1 (cg-RX-API-DMAC7.html)
EP (2) EP4036097A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024504257A (cg-RX-API-DMAC7.html)
KR (1) KR20230132811A (cg-RX-API-DMAC7.html)
CN (1) CN116745304A (cg-RX-API-DMAC7.html)
AR (1) AR124717A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022212601A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023014549A2 (cg-RX-API-DMAC7.html)
CA (1) CA3202780A1 (cg-RX-API-DMAC7.html)
IL (1) IL303825A (cg-RX-API-DMAC7.html)
MX (1) MX2023008250A (cg-RX-API-DMAC7.html)
TW (1) TW202239414A (cg-RX-API-DMAC7.html)
WO (1) WO2022162206A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021380963A1 (en) * 2020-11-20 2023-06-22 ETH Zürich Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases
AU2023313374A1 (en) * 2022-07-29 2025-02-13 Vifor (International) Ltd. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
TW202412815A (zh) * 2022-07-29 2024-04-01 西班牙商薩尼菲特治療公司 Ip5經取代化合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873355A (en) * 1987-05-29 1989-10-10 E. I. Du Pont De Nemours And Company Process for regioselectively preparing phosphorylated inositols and other cyclitols
EP0431197A1 (en) * 1989-06-28 1991-06-12 MITSUI TOATSU CHEMICALS, Inc. Myoinositol derivative and method of production thereof, and phosphorylating agent and its use
US5157140A (en) * 1986-11-26 1992-10-20 Perstorp Ab Esters of myo-inositol phosphate
JPH11508240A (ja) * 1995-06-07 1999-07-21 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 膜透過性第2メッセンジャー
CN102143754A (zh) * 2008-08-06 2011-08-03 巴利阿里群岛大学 含有结晶抑制物质的组合物
CN108367080A (zh) * 2015-12-11 2018-08-03 苏黎世联邦理工学院 用于病理性结晶的肌醇衍生物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755612A (en) * 1987-07-20 1988-07-05 Merck & Co., Inc. Intermediate compounds resulting from method for forming a dihydrogen-phosphate inositol
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
WO2002096404A1 (en) 2001-05-29 2002-12-05 Depomed Development Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
ES2762984T3 (es) 2015-12-11 2020-05-26 Eth Zuerich 4,6-di-(O-tiofosfato)-inositol-1,2,3,5-tetra-O-sulfato para la infección por C. difficile
JP7758319B2 (ja) * 2018-03-15 2025-10-22 株式会社ラフィーネインターナショナル 骨外組織における骨形成関連因子又は石灰化関連因子の発現抑制剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157140A (en) * 1986-11-26 1992-10-20 Perstorp Ab Esters of myo-inositol phosphate
US4873355A (en) * 1987-05-29 1989-10-10 E. I. Du Pont De Nemours And Company Process for regioselectively preparing phosphorylated inositols and other cyclitols
EP0431197A1 (en) * 1989-06-28 1991-06-12 MITSUI TOATSU CHEMICALS, Inc. Myoinositol derivative and method of production thereof, and phosphorylating agent and its use
JPH11508240A (ja) * 1995-06-07 1999-07-21 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 膜透過性第2メッセンジャー
CN102143754A (zh) * 2008-08-06 2011-08-03 巴利阿里群岛大学 含有结晶抑制物质的组合物
CN108367080A (zh) * 2015-12-11 2018-08-03 苏黎世联邦理工学院 用于病理性结晶的肌醇衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANTONIA E. SCHANTL等: ""Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers"", NATURE COMMUNICATIONS, vol. 11, no. 1, 31 December 2020 (2020-12-31), pages 721 *

Also Published As

Publication number Publication date
BR112023014549A2 (pt) 2023-10-10
WO2022162206A1 (en) 2022-08-04
IL303825A (en) 2023-08-01
AR124717A1 (es) 2023-04-26
EP4284809A1 (en) 2023-12-06
AU2022212601A9 (en) 2025-04-10
MX2023008250A (es) 2023-07-26
TW202239414A (zh) 2022-10-16
JP2024504257A (ja) 2024-01-31
CA3202780A1 (en) 2022-08-04
EP4036097A1 (en) 2022-08-03
US20240109924A1 (en) 2024-04-04
AU2022212601A1 (en) 2023-07-06
KR20230132811A (ko) 2023-09-18

Similar Documents

Publication Publication Date Title
EP2521711B1 (en) Quaternary ammonium salt prodrugs
US20240109924A1 (en) Ip4-4,6 substituted derivative compounds
EA026114B1 (ru) Макроциклические ингибиторы вирусов flaviviridae
KR20120087878A (ko) 1,3-프로판디설포닉 애시드의 수송을 위한 방법, 화합물 및 조성물
EA021758B1 (ru) Способ лечения болезни альцгеймера
WO2012150866A1 (en) Phosphoribosyltransferase inhibitors and uses thereof
CN119855595A (zh) 用于治疗异位钙化、抑制进展和预防异位钙化的ip4-4,6取代的衍生物化合物
CN112218878A (zh) Ntcp抑制剂
WO2023047399A1 (en) Cannabinoid-lipid conjugates, methods for producing the same and uses thereof
CN119630679A (zh) Ip5取代的化合物
US9328128B2 (en) Arylfluorophosphate inhibitors of intestinal apical membrane sodium/phosphate co-transport
EA050725B1 (ru) Замещенные производные соединений ip4-4,6
HK40094155A (en) Ip4-4,6 substituted derivative compounds
CN106946701B (zh) 一种水杨酸基富马酸盐衍生物及在治疗帕金森症和其他神经退行性疾病应用
CN103980148B (zh) 硬脂酰氨基酸盐及其制备方法和应用
HK40123408A (en) Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2025006856A1 (en) Htra1 inhibitors and uses thereof
EP1847270B1 (en) Use of amygdalin analogues for the treatment of psoriasis
AU2019314405A1 (en) Methods of activating microglial cells
HK1176348B (en) Quaternary ammonium salt prodrugs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40094155

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250826

Address after: St Gallen

Applicant after: Weifu (International) Co.,Ltd.

Country or region after: Switzerland

Address before: Palma, Mallorca, Balearic Islands, Spain

Applicant before: Sanifeld treatment Co.,Ltd.

Country or region before: Spain